In vivo antitumor evaluation of antibiotics. Selected results from the Drug Evaluation Program of the National Cancer Institute, U.S.A.

A summary is given of the in vivo screening results for selected antitumor antibiotics in various stages of the National Cancer Institute drug development program. In addition a brief description of general screening practices of the program is given. After long-term usage of leukemia L1210 as a primary screen, a new screening panel is being initiated with P388 leukemia as a prescreening system. Illustrative data on anguidine, actinomycin D, macromomycin, aclacinomycin, and other fermentation products are shown.